VIVACELL BIOTECHNOLOGY GMBH

Their core work

Vivacell Biotechnology is a small German biotech SME focused on the extraction, characterization, and application of bioactive compounds from plants — particularly aromatic plants, Mediterranean food plants, and their processing by-products. Their work sits at the intersection of phytochemistry and applied product development, translating plant-derived natural substances into cosmeceuticals and food safety applications. They bring industry-side expertise to academic research consortia, serving as a commercial anchor that connects laboratory-scale phytochemical research to real product development pipelines. With a particular emphasis on eco-friendly processing technologies, they apply green chemistry principles to valorize plant by-products that would otherwise be discarded.

What they specialise in

How they've shifted over time

With only two projects — both launched in 2016 — there is no meaningful temporal shift to report; the organization's H2020 engagement was concentrated in a single entry period rather than spread across the programme's lifetime. The first project (MediHealth) carried no indexable keywords, while EXANDAS provided the clearer signal: phytochemistry, essential oils by-products, and eco-friendly technologies. This suggests a progression from broad healthy-ageing plant research toward more specific aromatic-plant valorisation and commercial cosmeceutical applications, but the evidence base is too thin to call this a firm trend.

Based on limited data, Vivacell appears to be moving toward the commercial end of natural product development — specifically aromatic plant by-product valorisation for cosmeceuticals — rather than staying in broad health research.

How they like to work

Vivacell has participated exclusively as a non-leading partner in both H2020 engagements, joining large MSCA-RISE staff-exchange consortia rather than building or coordinating projects themselves. MSCA-RISE networks typically involve 8–15+ organisations, which explains the relatively high partner count (22 across 13 countries) despite having only two projects. This pattern suggests they join consortia to access research networks and international mobility, rather than to drive project agendas — a typical SME role in MSCA schemes.

Vivacell has built connections with 22 partner organisations across 13 countries through two MSCA-RISE projects — a broad international footprint for a two-project participant, characteristic of the RISE scheme's multi-partner structure. No geographic concentration is evident from the available data.

What sets them apart

Vivacell occupies a narrow but commercially relevant niche: a private biotech SME that can bridge phytochemical research with cosmeceutical and food safety product development, bringing industry realism into academic consortia. Few small German firms combine essential oil chemistry with eco-friendly by-product valorisation, which makes them a credible industry partner for projects that need a commercial endpoint beyond the lab. For consortium builders, they offer the SME-in-industry credential required by many EU schemes without the overhead or agenda of a large corporate partner.

Highlights from their portfolio

• EXANDAS
  The larger and more keyword-rich of the two projects (EUR 40,500), it defines Vivacell's clearest technical identity — aromatic plant by-product valorisation for cosmeceuticals using eco-friendly technologies.
• MediHealth
  Demonstrates Vivacell's broader natural-products background, connecting Mediterranean dietary plants to healthy ageing applications across a three-year international consortium.